

UCRL 581
Cy 91/A
C.2

UNIVERSITY OF
CALIFORNIA

*Radiation
Laboratory*

TWO-WEEK LOAN COPY

*This is a Library Circulating Copy
which may be borrowed for two weeks.
For a personal retention copy, call
Tech. Info. Division, Ext. 5545*

BERKELEY, CALIFORNIA

UCRL - 581
C.2

DISCLAIMER

This document was prepared as an account of work sponsored by the United States Government. While this document is believed to contain correct information, neither the United States Government nor any agency thereof, nor the Regents of the University of California, nor any of their employees, makes any warranty, express or implied, or assumes any legal responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by its trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof, or the Regents of the University of California. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or any agency thereof or the Regents of the University of California.

UNIVERSITY OF CALIFORNIA

Radiation Laboratory

Contract No. W-7405-eng-48

A STUDY OF THE EFFECT OF 2,3-DIMERCAPTOPROPANOL (BAL)


UPON THE METABOLISM OF PLUTONIUM

Bergene Kawin and D. Harold Copp

January 23, 1950

DECLASSIFIED

CAUTION



This document contains information affecting the
National Defense of the United States.
Its transmission or the disclosure of its contents
in any manner to an unauthorized person is pro-
hibited and may result in severe criminal penalties
under applicable Federal laws.

Berkeley, California

DECLASSIFIED

UCRL 581
Health and Biology

-2-

STANDARD DISTRIBUTION: SERIES A

Copy Numbers

Argonne National Laboratory	1-8
Armed Forces Special Weapons Project	9
Atomic Energy Commission, Washington	10-11
Battelle Memorial Institute	12
Brookhaven National Laboratory	13-16
Bureau of Medicine and Surgery	17
Carbide & Carbon Chemicals Corp. (K-25 Plant)	18-21
Carbide & Carbon Chemicals Corp. (Y-12 Plant)	22-25
Chicago Operations Office	26
Columbia University (Dunning)	27
Columbia University (Failla)	28
General Electric Company, Richland	29-34
Hanford Operations Office	35
Idaho Operations Office	36-37
Iowa State College	38
Knolls Atomic Power Laboratory	39-40
Los Alamos	41-43
Mallinckrodt Chemical Works	44
Massachusetts Institute of Technology (Kaufmann)	45
Mound Laboratory	46-48
National Advisory Committee for Aeronautics	49
National Bureau of Standards	50
Naval Radiological Defense Laboratory	51
NEPA Project	52
New Brunswick Laboratory	53
New York Operations Office	54-56
North American Aviation, Inc.	57
Oak Ridge National Laboratory	58-69
Patent Branch, Washington	70
Public Health Service	71
Sandia Laboratory	72
Sylvania Electric Products, Inc.	73
Technical Information Branch, ORE	74-88
UCLA Medical Research Laboratory (Warren)	89
University of California Radiation Laboratory	90-94
University of Chicago Toxicity Laboratory	95
University of Rochester	96-97
University of Washington	98
Western Reserve University (Friedell)	99-102
Westinghouse Electric Corporation	103

INFORMATION DIVISION
Radiation Laboratory
Univ. of California
Berkeley, California

A STUDY OF THE EFFECT OF 2,3-DIMERCAPTOPROPANOL (BAL)
UPON THE METABOLISM OF PLUTONIUM*

Bergene Kawin and D. Harold Copp.

Division of Physiology, University of California Medical School, and the
Crocker Radiation Laboratory; University of California, Berkeley, Calif.

The transuranic element, plutonium, presents a major health hazard. Its acute radiation toxicity, high degree of retention by the skeleton, and extremely low rate of elimination from the body accentuate its lethal nature. The number of workers engaged in the industrial production of this element in connection with the atomic energy program, as well as the investigative use of plutonium in the laboratory, intensifies this danger. For this reason considerable effort has been devoted to the search for possible methods of therapeutic treatment for plutonium poisoning.

The compound, 2,3-dimercaptopropanol (BAL), has been shown to be effective in the treatment of systemic poisoning produced by a number of metals. These include arsenic(1-4) mercury (5,6) cadmium (7) and antimony (8). More recently(9) BAL has been shown to increase the excretion, and lengthen the survival time, of animals injected with polonium. The efficacy of BAL in these cases is dependent upon its dithiol groups. The production of biochemical lesions by these metals is attributable to the inactivation of essential enzymes or tissue protein systems by combination of the metal with their prosthetic sulfhydryl groups. The addition of BAL results in the formation of a comparatively undissociable and stable BAL-metal complex. The removal of the metal through the formation of this complex effectively reactivates the enzyme system. The metal is excreted from the animal as the BAL-metal complex. By this general mechanism BAL removes the metal cation from the body.

*This document is based on work performed under Contract No. W-7405-eng-48-A for the Atomic Energy Commission.

The possible value of BAL in treatment of plutonium poisoning was investigated in the following experiment by studying its effect on experimentally injected plutonium.

DECLASSIFIED

Methods

Seventeen young adult female rats ranging in weight from 200 to 240 grams were each injected intramuscularly with 15 micrograms of hexavalent plutonium as the chloride (half-life 2.4×10^4 years) into the right front leg. The total volume of the injection in each case was 0.25 milliliters. The plutonium, in acid solution, was diluted with physiological saline. The final pH was about 3.0. Standards were prepared in duplicate.

The animals were separated into three groups. Group 1, consisting of seven animals, received no treatment. These animals served as controls. Groups 2 and 3, consisting of five animals each, received several injections of 10 milligrams of BAL in 0.1 milliliters of oil into the muscles of the hind legs. The animals of Group 2 received a single injection of BAL five hours prior to the plutonium injection, and nine injections of BAL spaced at four-hour intervals thereafter. The animals in the third group received only the nine injections following plutonium administration.

All animals were placed in separate metabolism cages to permit separate collections of excreta. The animals were fed ad libitum upon a stock diet. They lost 5 to 6 grams weight during the period of the experiment. The urine and feces collections were pooled for the individual animals for the periods 0-2 days and 3-8 days following the injection of plutonium.

At the end of the eighth day the animals were sacrificed and the liver, kidneys, right femur, right front leg, and the left front leg were removed separately. The residual portions of the animal were assayed together as 'carcass'. Assay of the plutonium in the tissues and excreta was done by the method described

by Scott et al (10). The difference between right and left front legs gave a measure of the plutonium remaining unabsorbed at the site of injection.

Results and Discussion

The results of the experiment are shown in Tables I and II, and Figure 1. Table I shows the distribution of the injected plutonium, expressed as percent of the administered dose. Values for the left front leg are not listed, since they were used to correct for the amount of plutonium remaining unabsorbed at the site of injection in the right front leg. It can be seen that about half of the plutonium was unabsorbed in all three groups. The figures obtained for the various tissues and the excreta showed no significant effects of the BAL treatment.

In Table II the distribution is expressed as a percentage of the plutonium absorbed from the injection site. Here, as in Table I, the distribution of plutonium in all three groups does not vary significantly. Following an initially high urinary elimination, the excretion of plutonium falls to a very low level. The fecal excretion remains consistently low. There appears to be a slightly greater uptake in the soft tissues (liver and kidneys) of the animals treated with BAL. In Group 3 the deposition of plutonium in the femur is somewhat lowered. However, when examined statistically, these differences appear to be of very slight significance.

In Figure 1 the data of Table II are presented graphically. Here the similarity of plutonium metabolism in both treated and untreated animals is demonstrated.

It has been shown previously (10) that, following the intramuscular injection of plutonium, 60 to 70 percent of the metal is accumulated in the skeleton. There is a very low rate of elimination. The results of this experiment would indicate that the distribution and excretion of plutonium is not significantly altered by the administration of BAL. The unreactivity of plutonium towards BAL is in contradistinction to the behavior of such heavy metals as arsenic, mercury and

polonium, which react with the sulfhydryl groups of BAL. It suggests that the mechanisms of the distribution and excretion of plutonium may be largely independent of the activity of sulfhydryl groups.

Summary

1. The effects of 2,3-dimercaptopropanol (BAL) upon the metabolism of intramuscularly injected Pu(VI) have been investigated.
2. The use of BAL produced no significant alterations in the distribution and excretion of plutonium as compared to the pattern shown by control animals.
3. The metabolism of plutonium does not appear to be related to sulfhydryl groups.
4. On the basis of its ineffectiveness in changing the metabolism of plutonium, BAL does not appear to be an effective therapeutic treatment for plutonium poisoning.

References

- (1) Eagle, H., Magnuson, H.J., and Fleischman, R., J. Clin. Invest., 25, 451 (1946)
- (2) Carleton, A.B., Peters, R.A., Stocken, L.A., Thompson, R.H.S., and Williams, D.I., J. Clin. Invest., 25, 497 (1946)
- (3) Longcope, W.T., Leutscher, J.A. Jr., Wintrobe, M.M., and Jager, V., J. Clin. Invest., 25, 528 (1946)
- (4) Leutscher, J.A. Jr., Eagle, H., and Longcope, W.T., J. Clin. Invest., 25, 534 (1946)
- (5) Gilman, A., Allen, R.P., Philips, F.S., and St. John, E., J. Clin. Invest., 25, 549 (1946)
- (6) Longcope, W.T., and Leutscher, J.A. Jr., J. Clin. Invest., 25, 557 (1946)
- (7) Gilman, A., Philips, F.S., Allen, R.P., and Koelle, E.S., J. Pharmacol., 87, Suppl., 85 (1946)
- (8) Braun, H.A., Lusky, L.M., and Calvery, H.O., J. Pharmacol., 87, Suppl., 119 (1946)
- (9) Hursh, J.B., Report UR-83 (1949)
- (10) Scott, K.G., Axelrod, D.J., Fisher, H., Crowley, J.F., and Hamilton, J.G., J. Biol. Chem., 176, 283 (1948)

TABLE I

THE EFFECTS OF BAL TREATMENT UPON THE DEPOSITION
AND EXCRETION OF INTRAMUSCULARLY INJECTED
PLUTONIUM

Part	<u>Percent of Dosage*</u>		
	Controls	Pretreated	Post-Treated
Liver	7.1 \pm 0.8**	8.0 \pm 1.3	8.1 \pm 1.3
Kidneys	0.7 \pm 0.1	1.3 \pm 0.6	0.8 \pm 0.1
Femur	1.8 \pm 0.1	1.5 \pm 0.1	1.1 \pm 0.3
Carcass	35.6 \pm 3.0	27.8 \pm 2.5	31.8 \pm 6.5
Unabsorbed in Injected Leg	43.5 \pm 2.6	53.0 \pm 5.0	48.4 \pm 5.9
Urine (0-2 day)	5.5 \pm 0.8	3.6 \pm 0.8	4.7 \pm 1.1
(3-8 day)	0.9 \pm 0.2	1.0 \pm 0.2	0.6 \pm 0.1
Total	6.4 \pm 0.8	4.6 \pm 0.8	5.3 \pm 1.3
Feces (0-2 day)	1.3 \pm 0.3	0.7 \pm 0.2	0.7 \pm 0.3
(3-8 day)	3.6 \pm 0.6	3.1 \pm 0.4	3.8 \pm 0.8
Total	4.9 \pm 0.4	3.8 \pm 0.6	4.5 \pm 1.1

*Values in this table have been adjusted to 100% recovery. The actual total recoveries approximated 89-90% \pm 6.0% in all groups. Carcass values have been corrected for the plutonium present in the right front leg bone as separate from the amount retained in the injected muscle of that leg.

**Standard error of the mean: S.E. = $\sqrt{\frac{\sum (x-\bar{x})^2}{n(n-1)}}$

TABLE II

THE EFFECTS OF BAL TREATMENT UPON THE DEPOSITION
AND EXCRETION OF INTRAMUSCULARLY INJECTED PLUTONIUM
CORRECTED FOR AMOUNT RETAINED AT INJECTION SITE

<u>Part</u>	<u>Percent of Dosage*</u>		
	Controls	Pre-Treated	Post-Treated
Liver	12.6 \pm 1.4	17.0 \pm 2.8	15.7 \pm 2.5
Kidneys	1.2 \pm 0.2	2.8 \pm 1.3	1.5 \pm 0.2
Femur	3.2 \pm 0.2	3.2 \pm 0.2	2.1 \pm 0.6
Carcass	63.0 \pm 5.3	59.1 \pm 5.3	61.7 \pm 12.6
Urine (0-2 day)	9.7 \pm 1.4	7.7 \pm 1.7	9.1 \pm 2.1
(3-8 day)	1.6 \pm 0.4	2.1 \pm 0.4	1.2 \pm 0.2
Total	11.3 \pm 1.4	9.8 \pm 1.7	10.3 \pm 2.5
Feces (0-2 day)	2.3 \pm 0.5	1.5 \pm 0.4	1.3 \pm 0.6
(3-8 day)	6.4 \pm 1.1	6.6 \pm 0.8	7.4 \pm 1.5
Total	8.7 \pm 0.7	8.1 \pm 1.3	8.7 \pm 2.1

*Values in this table are computed upon the amount of plutonium actually absorbed from the site of the injection.

FIGURE 1. THE EFFECTS OF INTENSIVE BAL TREATMENT ON THE DEPOSITION AND EXCRETION OF PLUTONIUM IN RATS

CONTROLS, NO BAL
 PRE-TREATED WITH BAL
 POST-TREATED WITH BAL

